drugset / Trial / NCT00101127

Docetaxel, Gemcitabine, and Filgrastim (G-CSF) or Pegfilgrastim in Treating Patients With Advanced, Persistent, or Recurrent Uterine Leiomyosarcoma

NCT00101127

Open-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy, such as docetaxel and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Colony-stimulating factors, such as G-CSF and pegfilgrastim, may increase the number of immune cells found in bone marrow or peripheral blood and may help the immune system recover from the side effects of chemotherapy. Giving docetaxel and gemcitabine together with G-CSF or pegfilgrastim may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving docetaxel and gemcitabine together with G-CSF or pegfilgrastim works in treating patients with advanced, persistent, or recurrent uterine leiomyosarcoma.

Timeline

Start
2003-12
Primary completion
2006-07
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Docetaxel Small molecule 100 mg/m2 Intravenous
Subject Gemcitabine Small molecule 900 mg/m2 Intravenous
Subject Pegfilgrastim Protein / enzyme biologic Subcutaneous
Subject filgrastim Protein / enzyme biologic Subcutaneous

Indications